Aptamer 学术简报 — therapeutic — 2026-06-18

自动生成 by RBTX Aptamer Tracker v0.1。 子主题 therapeutic：近 14 天 56 篇命中（aptamer 池 155 篇）。

评分公式：composite = 0.45×log(IF) + 0.35×log(cites_velocity) + 0.10×social + 0.10×recency_bonus；满分 100。

#1 [15.2] Engineered Lysosome-Targeted Protein Degradation via Hijacking Macropinocytosis.

Recently, targeted protein degradation (TPD) strategies have emerged as an effective tool for addressing undruggable targets in both biomedical research and the pharmaceutical industry, selectively binding proteins of interest and targeting them to the intracellular degradation machinery for degradation. However, the targeting of extracellular p...

#2 [14.3] A Biomimetic Dual-Targeting Nano-APA-Editor Reprograms the 3'UTR Landscape for Tongue Squamous Cell Carcinoma Therapy.

Targeting post-transcriptional dysregulation of tumor suppressors represents a new frontier in cancer therapy. Here, we identify the alternative polyadenylation (APA) regulator NUDT21 as a pivotal therapeutic target in oral squamous cell carcinoma (OSCC). NUDT21 is highly upregulated, correlating strongly with poor survival and advanced clinical...

#3 [14.0] Stability modification of therapeutic aptamers: from biostability bottlenecks to nuclease-resistant construct design.

Nucleic acid aptamers are synthetic, single-stranded oligonucleotides that bind targets with high affinity and specificity, enabling precise and programmable functional modulation. However, low biostability remains a key druggability bottleneck of therapeutic aptamers. In vivo enzymatic lability constitutes a primary pharmacokinetic barrier, imp...

#4 [13.4] Engineering human PEG10-based nanoparticles for RNA self-packaging, delivery and cancer therapy

PEG10 protein was recently uncovered to self-assemble and self-package its own mRNA into nanoparticles, but the particles require expensive transfection for production and have yet to be explored for cancer therapy. Here we develop a human PEG10-based nanoparticles (PBNPs) platform for cargo RNA self-packaging and delivery for cancer therapy. We...

#5 [12.6] Multifunctional DNA Nanoplatform Based on CuInS/ZnS QDs and Rolling Circle Amplification for Synergistic PTT/CDT/CT of Multidrug Resistant Cancer Cells.

Synergistic therapy holds significant potential in cancer diagnosis and treatment, yet faces substantial challenges such as nonspecific drug release and tumor multidrug resistance (MDR). Herein, we report a self-assembled DNA nanoplatform (ZCIS QDs@RD) based on CuInS/ZnS QDs (ZCIS QDs) and rolling circle amplification (RCA) for synergistic photo...

#6 [12.5] Aptamers: Current Applications in Leukemia Diagnostics and Therapeutics.

Aptamers are single-stranded synthetic oligonucleotides that bind noncovalently to targets with high affinity and selectivity. They are generated through an in vitro selection process known as Systematic Evolution of Ligands by Exponential Enrichment. Aptamers show significant promise in cancer diagnostics and therapeutics due to their specifici...

#7 [12.3] A Photosensitizer-Intercalated Programmable DNA System for Enhanced Photoimmunotherapy via Tumor Microenvironment Remodeling.

Photoimmunotherapy (PIT) has emerged as a minimally invasive therapeutic modality for cancer, offering high spatial precision and favorable therapeutic outcomes. However, the aggregation-caused quenching (ACQ) of photosensitizers and the hypoxic tumor microenvironment (TME) limit its overall efficacy. Herein, a DNA tetrahedron-based nanoplatform...

#8 [12.3] Protein Binding and Molecular Size Govern Molecular Transport into Dermal Interstitial Fluid.

Dermal interstitial fluid (ISF) has emerged as the leading frontier for real-time molecular monitoring due to its rapid equilibration with blood and its role in carrying biomarkers that may reflect health status. To access ISF, we and others have developed microneedle sensor arrays, composed of microscopic probes that penetrate the epidermis pai...

#9 [12.3] Enhancing small-molecule-mediated translational control through multivalent RNA aptamers.

The precise translational control of gene expression by small molecules through RNA-based switches holds considerable promise for both research and therapeutic developments. However, current high-performance RNA switches remain limited in adaptability, with strong responses typically constrained to a narrow set of specific ligand-aptamer pairs. ...

#10 [12.2] Programmable Chimeric Antigen Receptor T Cell Circuits With DNA Computing for Precision Tumor Therapy.

Chimeric antigen receptor (CAR) T cells, a promising cancer therapeutics, still face challenges in safety and efficacy due to the incapability to precisely regulate T cell activation. Here we develop a DNA-logic CAR (DL-CAR) system that enables programmable targeting and precise ablation of tumors with specific antigen combination patterns. The ...

Methodology